Obermatt
See Similar Stocks →

Black Diamond Therapeutics

NSQ:BDTX · US09203E1055
BiotechnologySmall

360

21
Medium confidence — indicative
Profit price—
Cash yield—
Price/Sales57
Price/Book63
Return on Capital74
Return on Equity80
Profit margins28

Cash truth not applicable for financial companies.

Sales growth26
Profit growth89
Reinvestment34
Price momentum8
Debt load35
Debt serviceability27
Liquidity30
Analyst ratings17
Expectations trend50
Market mood37
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Black Diamond Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2014
Employees28
Websiteblackdiamondtherapeutics.com
ISINUS09203E1055
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
GeneticsChronic DiseasesNeurologyOncologyCentral Nervous SystemBiotechnologyLife ScienceMedical

Description

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, develops MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of gene…

Analysis

Middle-of-the-road

Black Diamond Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is stretched. The company scores 0/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
1
2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
57
—
—
—
Price/Earnings
24
—
—
—
Price/Book
63
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
59
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Black Diamond Therapeutics with its peers
Nuvalent
NSQ:NUVL
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Revolution Medicines
NSQ:RVMD
32
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tyra Biosciences
NSQ:TYRA
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
ArriVent BioPharma
NMQ:AVBP
89
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Galectin Therapeutics
NAQ:GALT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immuneering
NMQ:IMRX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →